BrightPath Biotherapeutics Co (TSE:4594) E10: 円-34.65 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4594 BrightPath Biotherapeutics Co Ltd TSE:4594
35 GF Score
Price 円53.00
! 3 Warning Signs
View Full Analysis

What is BrightPath Biotherapeutics Co E10?

BrightPath Biotherapeutics Co TSE:4594 35 E10 is 円-34.65 as of Mar. 2026. GuruFocus rates TSE:4594 with a GF Score™ of 35/100. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

BrightPath Biotherapeutics Co's adjusted earnings per share data for the three months ended in Mar. 2026 was 円1.900. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is 円-34.65 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-08-25), BrightPath Biotherapeutics Co's current stock price is 円53.00. BrightPath Biotherapeutics Co's E10 for the quarter that ended in Mar. 2026 was 円-34.65. BrightPath Biotherapeutics Co's Shiller PE Ratio of today is .


BrightPath Biotherapeutics Co  (TSE:4594) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


BrightPath Biotherapeutics Co E10 Related Terms


BrightPath Biotherapeutics Co E10 Historical Data

* Premium members only.

The historical data trend for BrightPath Biotherapeutics Co's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BrightPath Biotherapeutics Co E10 Chart

BrightPath Biotherapeutics Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -34.65

BrightPath Biotherapeutics Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -36.20 0.00 -35.71 -34.65 0.00

TSE:4594 vs VRTX, REGN, RVMD: E10 Comparison

For the Biotechnology subindustry, BrightPath Biotherapeutics Co's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BrightPath Biotherapeutics Co Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BrightPath Biotherapeutics Co's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where BrightPath Biotherapeutics Co's Shiller PE Ratio falls into.


TSE:4594
35GF Score
BrightPath Biotherapeutics Co Ltd TSE:4594
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BrightPath Biotherapeutics Co E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BrightPath Biotherapeutics Co's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.9/112.7000*112.7000
=1.900

Current CPI (Mar. 2026) = 112.7000.

BrightPath Biotherapeutics Co Quarterly Data

per share eps CPI Adj_EPS
201603 -6.317 97.900 -7.272
201606 -5.970 98.100 -6.859
201609 -8.610 98.000 -9.902
201612 -6.870 98.400 -7.868
201703 -11.290 98.100 -12.970
201706 -7.080 98.500 -8.101
201709 -11.370 98.800 -12.970
201712 -13.070 99.400 -14.819
201803 -9.730 99.200 -11.054
201806 -13.940 99.200 -15.837
201809 -10.370 99.900 -11.699
201812 -10.780 99.700 -12.186
201903 -9.868 99.700 -11.155
201906 -9.940 99.800 -11.225
201909 -10.001 100.100 -11.260
201912 -11.900 100.500 -13.345
202003 -12.360 100.300 -13.888
202006 -9.520 99.900 -10.740
202009 -7.530 99.900 -8.495
202012 -10.270 99.300 -11.656
202103 -8.820 99.900 -9.950
202106 -7.930 99.500 -8.982
202109 -6.270 100.100 -7.059
202112 -6.772 100.100 -7.624
202203 -7.590 101.100 -8.461
202206 -9.750 101.800 -10.794
202209 -4.450 103.100 -4.864
202212 -6.710 104.100 -7.264
202303 -4.138 104.400 -4.467
202306 -4.700 105.200 -5.035
202309 -4.110 106.200 -4.362
202312 -6.330 106.800 -6.680
202403 -3.070 107.200 -3.228
202406 -4.660 108.200 -4.854
202409 -2.450 108.900 -2.535
202503 0.000 111.100 0.000
202506 -2.590 111.700 -2.613
202509 0.000 112.000 0.000
202512 -9.070 113.000 -9.046
202603 1.900 112.700 1.900

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of 円-34.65 mean?
BrightPath Biotherapeutics Co (TSE:4594) has a E10 of 円-34.65 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on BrightPath Biotherapeutics Co and its competitors.
Is BrightPath Biotherapeutics Co's E10 too high?
BrightPath Biotherapeutics Co's current E10 is 円-34.65. Overall, BrightPath Biotherapeutics Co has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does BrightPath Biotherapeutics Co's E10 compare to VRTX and REGN?
BrightPath Biotherapeutics Co's E10 of 円-34.65 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on BrightPath Biotherapeutics Co and its competitors. BrightPath Biotherapeutics Co's current E10 is 円-34.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BrightPath Biotherapeutics Co stock overvalued right now?
BrightPath Biotherapeutics Co (TSE:4594) has a current E10 of 円-34.65. The current E10 is 円-34.65. BrightPath Biotherapeutics Co's overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For BrightPath Biotherapeutics Co (TSE:4594), the current E10 is 円-34.65 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BrightPath Biotherapeutics Co Business Description

Address 2-2-4 Kojimachi, Kojimachi Central Building 7th Floor, Chiyoda-ku, Tokyo, JPN
BrightPath Biotherapeutics Co Ltd is a biopharmaceutical venture company. It is engaged in developing novel cancer immunotherapeutics. Its products include two candidate products: ITK-1 and GRN-1201 which are in the clinical trial stage.
35GF Score

Get the complete analysis for TSE:4594

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円53.00
Price